Melanotan II (10mg) + PT-141 (10mg) Stack
Components: Melanotan II + PT-141 (Bremelanotide)
A melanocortin receptor stack combining Melanotan II (daily loading protocol) and PT-141/Bremelanotide (on-demand protocol). Targets skin pigmentation and sexual function through complementary MC receptor pathways.
Stack Components
This stack uses 2 separate vials — each peptide is reconstituted independently.
| Peptide | Dose | Frequency | Timing | Route |
|---|---|---|---|---|
| Melanotan II Cyclic u03b1-MSH analogue; activates MC1R (pigmentation) and MC3R/MC4R (sexual function); daily loading builds melanin levels | 250 mcg (Week 1) u2192 500 mcg (Week 2) u2192 750 mcg (Weeks 3u20134) u2192 1000 mcg (Weeks 5+); maintenance 500u20131000 mcg 2u20133u00d7/week | Once daily (loading); 2u20133u00d7 per week (maintenance) | Consistent time daily; evening preferred | SubQ |
| PT-141 (Bremelanotide) FDA-approved (Vyleesi) cyclic melanocortin agonist for HSDD; activates MC3R/MC4R without significant pigmentation activity | 500u2013750 mcg (initial/titration) u2192 1000u20131500 mcg (standard) u2192 1750 mcg (full FDA-approved dose) | On-demand (u226545 min before activity); max 1 dose per 24 hours; max 8 doses per month | At least 45 minutes before anticipated sexual activity | SubQ |
Reconstitution Guide
Each peptide in this stack is a separate vial. Reconstitute them one at a time using the parameters below.
Melanotan II
SubQPT-141 (Bremelanotide)
SubQAlways use bacteriostatic water to reconstitute each vial. Draw from separate vials — do not mix in the same syringe unless your protocol specifies a shared injection.
Protocol Timeline
Full 8–16 weeks (Melanotan II loading + maintenance; PT-141 on-demand throughout) cycle breakdown.
Melanotan II: 250 mcg (7.5 units) once daily. PT-141 (if using): 500u2013750 mcg on-demand. Nausea and flushing are most pronounced in the first week of Melanotan II. Administer Melanotan II in the evening to minimize daytime discomfort.
Melanotan II: advance to 500 mcg (15 units) once daily. Side effects typically begin to diminish. Initial pigmentation changes may become visible around weeks 2u20133 with UV exposure.
Melanotan II: advance to 750 mcg (22 units) once daily. Visible pigmentation development with appropriate UV exposure. PT-141 on-demand as needed.
Melanotan II: 1000 mcg (30 units) once daily until target pigmentation is achieved. PT-141 on-demand as needed (max 8 doses/month).
Melanotan II: transition to 500u20131000 mcg administered 2u20133u00d7 per week to maintain pigmentation. PT-141 continues on-demand throughout. Monitor for any changes in moles or skin lesions.
Synergy Notes
Both PT-141 (bremelanotide) and Melanotan II are cyclic melanocortin peptide analogues acting on MC3R and MC4R in the CNS. PT-141 is a metabolite of Melanotan II, developed specifically for sexual function with reduced pigmentation activity. Melanotan II retains both pigmentation and sexual function properties. This stack allows targeted on-demand use of PT-141 for sexual function while Melanotan II's daily loading protocol establishes sustained pigmentation and background MC receptor activation. The two are used on separate schedules — Melanotan II daily, PT-141 only on-demand.
What to Expect
Week 1: Nausea, flushing, possible facial redness (Melanotan II). Weeks 2–4: Nausea diminishes; initial visible tanning with UV exposure. Weeks 5–8: Target pigmentation established; reduce Melanotan II to maintenance. PT-141 effects typically onset within 45–90 minutes of administration.
Questions about Melanotan II (10mg) + PT-141 (10mg) Stack
Yes u2014 PT-141 (bremelanotide, brand name Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women at the 1.75 mg dose. Research peptide versions are not pharmaceutical-grade and not FDA-approved for human use.
UV exposure (natural or controlled tanning) enhances Melanotan II's pigmentation effects. Some pigmentation can occur without UV, but results are typically more pronounced with gradual, controlled UV exposure. Use appropriate sun protection to minimize UV damage risk.
They can be used on the same day, but on separate schedules u2014 Melanotan II at its regular daily dosing time, PT-141 at least 45 minutes before activity as needed. Do not mix in the same vial or syringe.
No more than 1 dose per 24 hours and no more than 8 doses per month, based on the FDA prescribing information for bremelanotide.
Yes u2014 Melanotan II can darken existing moles and nevi due to melanin stimulation. Baseline documentation of skin lesions and regular monitoring during use is advised. Consult a dermatologist if new or changing lesions appear.
Research Use Disclaimer
This content is for educational purposes only and does not constitute medical advice. For research use only.